CRASH 3 – clinical randomisation of an antifibrinolytic in significant head injury

The CRASH-3 trial is being conducted to assess the effect of tranexamic acid on risk of death or disability in patients with Traumatic Brain Injury (TBI), which can cause bleeding in the brain. If left to continue, it can create pressure that can lead to further damage that will result in death or permanent disability. By conducting this trial, important evidence is being collected to help determine if tranexamic acid is an effective treatment for patients with TBI. Read more at tranexamic acid